References
- Enquête de prévalence des infections associées aux soins. INVS; 2012 [Internet]. [cited 2017 Jan 20]. Available from: http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2013/Enquete-nationale-de-prevalence-des-infections-nosocomiales-et-des-traitements-anti-infectieux-en-etablissements-de-sante-France-mai-juin-2012
- Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012 [Internet]. [ cited 2017 Jan 20]. Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=865
- Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370:1198.
- Marchetti A, Rossiter R. Economic burden of healthcare-associated infection in US acute care hospitals: societal perspective. J Med Econ. 2013;16:1399–1404.
- Lamarsalle L, Hunt B, Schauf M, et al. Evaluating the clinical and economic burden of healthcare-associated infections during hospitalization for surgery in France [Internet]. Epidemiol Amp Infect. 2013. cited 2016 Dec 8. Available from /core/journals/epidemiology-and-infection/article/div-classtitleevaluating-the-clinical-and-economic-burden-of-healthcare-associated-infections-during-hospitalization-for-surgery-in-francediv/47F40B2BF4623A686A2C0F291CCC5DA0.
- Ling ML, Apisarnthanarak A, Madriaga G. The burden of healthcare-associated infections in Southeast Asia: a systematic literature review and meta-analysis. Clin Infect Dis. 2015;60:1690–1699.
- Kanamori H, Weber DJ, DiBiase LM, et al. Longitudinal trends in all healthcare-associated infections through comprehensive hospital-wide surveillance and infection control measures over the past 12 years: substantial burden of healthcare-associated infections outside of intensive care units and “other” types of infection. Infect Control Hosp Epidemiol. 2015;36:1139–1147.
- Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368:533–542.
- Centers for disease control and prevention. Antibiotic resistant threats in the United States [Internet], 2013. [cited 2017 Dec 20]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
- Chen L, Todd R, Kiehlbauch J, et al. Notes from the field: pan-resistant New Delhi metallo-beta-lactamase-producing klebsiella pneumoniae - washoe county, Nevada, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:33.
- Morbidité et mortalité des infections à bactéries multi-résistantes aux antibiotiques en France en 2012. Étude burden BMR, rapport - Juin 2015. Saint-Maurice : institut de veille sanitaire [Internet]; 2015. 21 p. [cited 2017 Jan 20]. Available from: http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2015/Morbidite-et-mortalite-des-infections-a-bacteries-multi-resistantes-aux-antibiotiques-en-France-en-2012
- Knisely JM, Liu B, Ranallo RT, et al. Vaccines for Healthcare-associated Infections: promise and Challenge. Clin Infect Dis. 2016;63:657–662.
- Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant streptococcus pneumoniae. N Engl J Med. 2006;354:1455–1463.
- Dodet B, Goldmann D, Fabry F, et al. Immunological approaches against nosocomial infections. Proceedings of an international workshop. Veyrier-du-Lac, France, 2003 Nov 19–21. Vaccine.2004; 22:Suppl 1:S1–54.
- Botelho-Nevers E, Verhoeven P, Paul S, et al. Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage. Expert Rev Vaccines. 2013;12:1249–1259.
- Verhoeven PO, Gagnaire J, Haddar CH, et al. Identifying Hemodialysis Patients With the Highest Risk of Staphylococcus aureus Endogenous Infection Through a Simple Nasal Sampling Algorithm. Medicine (Baltimore). 2016;95:e3231.
- Bruyère R, Vigneron C, Bador J, et al. Significance of prior digestive colonization with extended-spectrum β-lactamase-producing enterobacteriaceae in patients with ventilator-associated pneumonia. Crit Care Med. 2016;44:699–706.
- Nissle K, Kopf D, Rösler A. Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic clostridium difficile among geriatric in-patients. BMC Geriatr. 2016;16:185.
- Sydnor E, Perl TM. Healthcare providers as sources of vaccine-preventable diseases. Vaccine. 2014;32:4814–4822.
- Russotto V, Cortegiani A, Raineri SM, et al. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. J Intensive Care. 2015;3:54.
- Rouveix E, Greffe S, Dupont C, et al. [Low vaccination coverage against influenza in elderly hospitalized in France]. Rev Med Interne. 2013;34:730–734.
- Karchmer AW. Nosocomial bloodstream Infections: organisms, risk factors, and implications. Clin Infect Dis. 2000;31:S139–S143.
- Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? Hum.Vaccines Immunother. 2016;12:239.
- Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30:1413–1424.
- Vanhems P, Bénet T, Munier-Marion E. Nosocomial influenza: encouraging insights and future challenges. Curr Opin Infect Dis. 2016;29:366–372.
- Rey D, Piroth L, Wendling M-J, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15:1283–1291.
- Pagani L, Thomas Y, Huttner B, et al. Transmission and effect of multiple clusters of seasonal influenza in a Swiss geriatric hospital. J Am Geriatr Soc. 2015;63:739–744.
- Chan T-C, Fan-Ngai Hung I, Ka-Hay Luk J, et al. Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. J Am Med Dir Assoc. 2014;15:226.e1–6.
- Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses. 2013;7(Suppl 2):72–75.
- Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34:6681–6690.
- Vaccine recommendations and coverage [Internet]. [ cited 2017 Apr 21]. Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/Vaccination-programmes-and-coverage.aspx
- Prevention and control of seasonal influenza with vaccines | MMWR [Internet]. [ cited 2017 Apr 21]. Available from: https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm
- DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–645.
- McElhaney JE, Beran J, Devaster J-M, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13:485–496.
- Liebowitz D, Lindbloom JD, Brandl JR, et al. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. 2015;15:1041–1048.
- Dormitzer P, Tsai T, Giudice GD. New technologies for influenza vaccines. Hum Vaccines Immunother. 2012;8:45–58.
- Vemula SV, Sayedahmed EE, Sambhara S, et al. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017:1–14.
- Ogilvie I, Khoury H, Goetghebeur MM, et al. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012;12:62.
- Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis. 2013;13:112.
- HCSP. Infections à rotavirus : suspension des recommandations de vaccination des nourrissons [Internet]. Paris: Haut Conseil de la Santé Publique; 2015 [cited 2017 Jan 23]. Available from: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=501
- Botelho-Nevers E, Gautret P, Biellik R, et al. Nosocomial transmission of measles: an updated review. Vaccine. 2012;30:3996–4001.
- Mipatrini D, Stefanelli P, Severoni S, et al. Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence. Pathog Glob Health. 2017;111:59–68.
- Mipatrini D, Addario SP, Bertollini R, et al. Access to healthcare for undocumented migrants: analysis of avoidable hospital admissions in Sicily from 2003 to 2013. Eur J Public Health. 2017;27:459–464.
- Verhoeven PO, Gagnaire J, Botelho-Nevers E, et al. Detection and clinical relevance of Staphylococcus aureus nasal carriage: an update. Expert Rev Anti Infect Ther. 2014;12:75–89.
- Tong SYC, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603–661.
- Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:273–279.
- Lee BY, Wiringa AE, Bailey RR, et al. Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis. Vaccine. 2010;28:2465–2471.
- Song Y, Tai JHY, Bartsch SM, et al. The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine. 2012;30:3675–3682.
- Verkaik NJ, de Vogel CP, Boelens HA, et al. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J Infect Dis. 2009;199:625–632.
- Flannagan RS, Heit B, Heinrichs DE. Antimicrobial mechanisms of macrophages and the immune evasion strategies of Staphylococcus aureus. Pathog Basel Switz. 2015;4:826–868.
- Bröker BM, Holtfreter S, Bekeredjian-Ding I. Immune control of Staphylococcus aureus - regulation and counter-regulation of the adaptive immune response. Int J Med Microbiol IJMM. 2014;304:204–214.
- Fowler VG, Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20(Suppl 5):66–75.
- Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–496.
- Fattom A, Matalon A, Buerkert J, et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccines Immunother. 2015;11:632–641.
- Creech CB, Johnson BG, Alsentzer AR, et al. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine. 2009;28:256–260.
- Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. Jama. 2013;309:1368–1378.
- McNeely TB, Shah NA, Fridman A, et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccines Immunother. 2014;10:3513–3516.
- Karauzum H, Haudenschild CC, Moore IN, et al. Lethal CD4 T cell responses induced by vaccination against Staphylococcus aureus bacteremia. J Infect Dis. 2017;215:1231–1239.
- Nissen M, Marshall H, Richmond P, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015;33:1846–1854.
- Proctor RA. Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges. Eur Cell Mater. 2015;30:315–326.
- Creech CB, Frenck RW, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: results of a randomised trial. Vaccine. 2017;35:385–394.
- Schmidt CS, White CJ, Ibrahim AS, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine. 2012;30:7594–7600.
- Yeaman MR, Filler SG, Schmidt CS, et al. Applying convergent immunity to innovative vaccines targeting Staphylococcus aureus. Front Immunol. 2014;5:463.
- Jullian-Desayes I, Landelle C, Mallaret M-R, et al. Clostridium difficile contamination of health care workers’ hands and its potential contribution to the spread of infection: review of the literature. Am J Infect Control. 2017;45:51–58.
- Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut; 2017 Apr;66(4):569–580.
- Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55(Suppl 2):S88–92.
- van Kleef E, Deeny SR, Jit M, et al. The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. Vaccine. 2016;34:5562–5570.
- Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–1548.
- Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccines Immunother. 2014;10:1466–1477.
- Ghose C, Kelly CP. The prospect for vaccines to prevent Clostridium difficile infection. Infect Dis Clin North Am. 2015;29:145–162.
- de Bruyn G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized phase 2 clinical trial. Vaccine. 2016;34:2170–2178.
- Study of a candidate Clostridium difficile toxoid vaccine in subjects at risk for C. difficile infection - full text view - clinicaltrials.gov [Internet]. [ cited 2017 Dec 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01887912
- Vidunas E, Mathews A, Weaver M, et al. Production and characterization of chemically inactivated genetically engineered clostridium difficile toxoids. J Pharm Sci. 2016;105:2032–2041.
- Sheldon E, Kitchin N, Peng Y, et al. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine. 2016;34:2082–2091.
- Search of: pfizer | clostridium difficile - list results - clinicaltrials.gov [Internet]. [ cited 2017 Dec 26]. Available from: https://clinicaltrials.gov/ct2/results?cond=Clostridium+Difficile&term=Pfizer&cntry=&state=&city=&dist=
- Search of: valneva Clostridium difficile vaccine - list results - clinicaltrials.gov [Internet]. [ cited 2017 Jan 24]. Available from: https://clinicaltrials.gov/ct2/results?term=Valneva+Clostridium+difficile+vaccine&Search=Search
- News – valneva investors & media [Internet]. [ cited 2017 Jan 24]. Available from: http://www.valneva.com/en/investors-media/news/2016#249
- Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014;13:507–519.
- Vincent J-L. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 2014;9:457–463.
- Search of: escherichia coli vaccine - List Results - ClinicalTrials.gov [Internet]. [ cited 2017 Jan 24]. Available from: https://clinicaltrials.gov/ct2/results?term=Escherichia+coli+vaccine&Search=Search&view=record
- Ahmad TA, El-Sayed LH, Haroun M, et al. Development of immunization trials against Klebsiella pneumoniae. Vaccine. 2012;30:2411–2420.
- Rosenthal VD, Al-Abdely HM, El-Kholy AA, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010-2015: device-associated module. Am J Infect Control. 2016;44:1495–1504.
- Lee W-H, Choi H-I, Hong S-W, et al. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med. 2015;47:e183.
- Garcia-Quintanilla M, Pulido MR, McConnell MJ. First steps towards a vaccine against Acinetobacter baumannii. Curr Pharm Biotechnol. 2013;14:897–902.
- Chiang M-H, Sung W-C, Lien S-P, et al. Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Hum Vaccines Immunother. 2015;11:1065–1073.
- Huang W, Wang S, Yao Y, et al. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep. 2016;6:37242.
- Kim OY, Hong BS, Park K-S, et al. Immunization with escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol Baltim Md. 1950;2013(190):4092–4102.
- Pfaller MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016;54:1–22.
- Search of: candida vaccine - list results - clinicaltrials.gov [Internet]. [ cited 2017 Jan 24]. Available from: https://clinicaltrials.gov/ct2/results?term=Candida+vaccine&Search=Search
- French CE, McKenzie BC, Coope C, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses. 2016;10:268–290.
- Search of: respiratory syncytial virus vaccine - list results - clinicaltrials.gov [Internet]. [ cited 2017 Jan 24]. Available from: https://clinicaltrials.gov/ct2/results?term=respiratory+syncytial+virus+vaccine&Search=Search
- Rajagopalan S, Yoshikawa Thomas T. Norovirus infections in long‐term care facilities. J Am Geriatr Soc. 2016;64:1097–1103.
- Verstraeten T, Cattaert T, Harris J, et al. Estimating the burden of medically attended norovirus gastroenteritis: modeling linked primary care and hospitalization datasets. J Infect Dis. 2017;216:957–965.
- Leroux-Roels G, Cramer JP, Mendelman PM, et al. Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial. J Infect Dis. 2018;217:597–607.
- Updated recommendations for use of VariZIG — united states [Internet], 2013. [cited 2017 Mar 14]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6228a4.htm
- Vaccination contre la varicelle [Internet]. [ cited 2017 Jan 31]. Available from: http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=5
- Young MK, Nimmo GR, Cripps AW, et al. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014;CD010056.
- Dare RK, Talbot TR. Health care-acquired viral respiratory diseases. Infect Dis Clin North Am. 2016;30:1053–1070.
- Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14:737–738.
- Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–317.
- Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes. J Antimicrob Chemother. 2012;67:2785–2787.
- Cywes-Bentley C, Skurnik D, Zaidi T, et al. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A. 2013;110:E2209–2218.
- Skurnik D, Roux D, Pons S, et al. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71:927–935.
- Søe NH, Jensen NV, Jensen AL, et al. Active and Passive Immunization Against Staphylococcus aureus Periprosthetic Osteomyelitis in Rats. Vivo Athens Greece. 2017;31:45–50.
- Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther. 2010;10:1049.
- Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of Staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009;53:2879.
- Prevention of S. Aureus Pneumonia study in heavily colonized, mechanically ventilated subjects - full text view - clinicaltrials.gov [Internet]. [ cited 2017 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02940626?term=staphylococcus+aureus+and+antibody&rank=15
- Aurexis® in cystic fibrosis subjects chronically colonized with staphylococcus aureus in their lungs - full text view - clinicaltrials.gov [Internet]. [ cited 2017 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT00198289?term=staphylococcus+aureus+and+antibody&rank=20
- Fine P, Eames K, Heymann DL. “Herd Immunity”: a rough guide. Clin Infect Dis. 2011;52:911–916.
- Chen SY, Anderson S, Kutty PK, et al. Health care–associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis. 2011;203:1517–1525.
- Maltezou HC, Ftika L, Theodoridou M. Nosocomial pertussis in neonatal units. J Hosp Infect. 2013;85:243–248.
- Maltezou HC, Poland GA. Vaccination policies for healthcare workers in Europe. Vaccine. 2014;32:4876–4880.
- Paterson P, Meurice F, Stanberry LR, et al. Vaccine hesitancy and healthcare providers. Vaccine. 2016 Dec 20;34(52):6700–6706.
- Killian M, Detoc M, Berthelot P, et al. Vaccine hesitancy among general practitioners: evaluation and comparison of their immunisation practice for themselves, their patients and their children. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2016;35:1837–1843.
- Harrison N, Brand A, Forstner C, et al. Knowledge, risk perception and attitudes toward vaccination among Austrian health care workers: A cross-sectional study. Hum Vaccines Immunother. 2016;12:2459–2463.
- Taddei C, Ceccherini V, Niccolai G, et al. Attitude toward immunization and risk perception of measles, rubella, mumps, varicella, and pertussis in health care workers working in 6 hospitals of Florence, Italy 2011. Hum Vaccines Immunother. 2014;10:2612–2622.
- Duffell EF, van de Laar MJW, Amato-Gauci AJ. Enhanced surveillance of hepatitis B in the EU, 2006–2012. J Viral Hepat. 2015;22:581–589.
- Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med. 1996;334:549–554.
- Haviari S, Bénet T, Saadatian-Elahi M, et al. Vaccination of healthcare workers: a review. Hum Vaccines Immunother. 2015;11:2522.
- Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258:1197–1206.
- Vasilevska M, Ku J, Fisman DN. Factors associated with healthcare worker acceptance of vaccination: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2014;35:699–708.
- Porretta A, Quattrone F, Aquino F, et al. A nosocomial measles outbreak in Italy. 2017 February-April. Eurosurveillance Internet. 2017. cited 2017 Oct 11; 22. Available from https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pmc/articles/PMC5572940/
- Botelho-Nevers E, Cassir N, Minodier P, et al. Measles among healthcare workers: a potential for nosocomial outbreaks. Euro Surveill. 2011 Jan 13;16(2). pii: 19764.
- Review of outbreaks and barriers to MMR vaccination coverage among hard-to-reach populations in Europe Venice II Consortium – september [Internet] 2012. [cited 2017 Jan 24]. Available from: http://ecdc.europa.eu/en/publications/Publications/MMR-vaccination-hard-to-reach-population-review-2013.pdf
- Hees L, Afroukh N, Floret D. Couverture vaccinale du personnel hospitalier du service d’urgences et de réanimation pédiatriques de l’hôpital Édouard-Herriot de Lyon en 2007, concernant la grippe, la coqueluche, la varicelle et la rougeole. Arch Pédiatrie. 2009;16:14–22.
- Fiebelkorn AP, Seward JF, Orenstein WA. A global perspective of vaccination of healthcare personnel against measles: systematic review. Vaccine. 2014;32:4823–4839.
- Fiebelkorn AP, Redd SB, Kuhar DT. Measles in healthcare facilities in the united states during the post-elimination Era, 2001-2014. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61:615.
- Urbiztondo L, Broner S, Costa J, et al. Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain. Hum Vaccines Immunother. 2015;11:293–297.
- Meade BD, Plotkin SA, Locht C. Possible options for new pertussis vaccines. J Infect Dis. 2014;209:S24–S27.
- Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56:1248–1254.
- Faure E, Cortot C, Gosset D, et al. Vaccinal status of healthcare students in Lille. Med Mal Infect. 2013;43:114–117.
- O’Reilly F, Dolan GP, Nguyen-Van-Tam J, et al. Practical prevention of nosocomial influenza transmission, ‘a hierarchical control’ issue. Occup Med. 2015;65:696–700.
- Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36–44.
- Frenzel E, Chemaly RF, Ariza-Heredia E, et al. Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. Am J Infect Control. 2016;44:1016–1021.
- De Serres G, Skowronski DM, Ward BJ, et al. Influenza vaccination of healthcare workers: critical analysis of the evidence for patient benefit underpinning policies of enforcement. PLoS One. 2017;12:e0163586.
- Smith DJ, Forrest S, Ackley DH, et al. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci. 1999;96:14001–14006.
- McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against Influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59:1375–1385.
- Saito N, Komori K, Suzuki M, et al. Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: a test-negative case-control study in Japan. Vaccine. 2017;35:687–693.
- Cheng AC, Macartney KK, Waterer GW, et al. Repeated vaccination does not appear to impact on influenza vaccine effectiveness against hospitalisation with confirmed influenza. Clin Infect Dis. 2017 Jun 1;64(11):1564–1572.
- Marcu A, Rubinstein H, Michie S, et al. Accounting for personal and professional choices for pandemic influenza vaccination amongst English healthcare workers. Vaccine. 2015;33:2267–2272.
- Kadi Z, Atif M-L, Brenet A, et al. Barriers of influenza vaccination in health care personnel in France. Am J Infect Control. 2016;44:361–362.
- Edwards F, Masick KD, Armellino D. Impact of the flu mask regulation on health care personnel influenza vaccine acceptance rates. Am J Infect Control. 2016;44:1154–1157.
- Dorribo V, Lazor-Blanchet C, Hugli O, et al. Health care workers’ influenza vaccination: motivations and mandatory mask policy. Occup Med. 2015;65:739–745.
- Podczervinski S, Stednick Z, Helbert L, et al. Comparison of “Carrot-vs.-Stick” approaches to employee influenza vaccination in a large cancer center with high baseline compliance rates. Am J Infect Control. 2015;43:228.
- Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361–381.
- Antela A, Fortún J, Navas E, et al. [Nosocomial varicella: study of an epidemic outbreak among immunosuppressed patients]. Enferm Infecc Microbiol Clin. 1991;9:357–360.
- Apisarnthanarak A, Kitphati R, Tawatsupha P, et al. Outbreak of varicella-zoster virus infection among Thai healthcare workers. Infect Control Hosp Epidemiol. 2007;28:430–434.
- Faoagali JL, Darcy D. Chickenpox outbreak among the staff of a large, urban adult hospital: costs of monitoring and control. Am J Infect Control. 1995;23:247–250.
- Wu M-F, Yang Y-W, Lin W-Y, et al. Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. J Hosp Infect. 2012;80:162–167.
- Kang J-H, Park YS, Park SY, et al. Varicella seroprevalence among health care workers in Korea: validity of self-reported history and cost-effectiveness of prevaccination screening. Am J Infect Control. 2014;42:885–887.
- Almuneef M, Memish ZA, Abbas ME, et al. Screening healthcare workers for varicella-zoster virus: can we trust the history? Infect Control Hosp Epidemiol. 2004;25:595–598.
- Ndumbe PM, Cradock-Watson JE, MacQueen S, et al. Immunisation of nurses with a live varicella vaccine. Lancet Lond Engl. 1985;1:1144–1147.
- Chodick G, Ashkenazi S, Livni G, et al. Cost-effectiveness of varicella vaccination of healthcare workers. Vaccine. 2005;23:5064–5072.
- Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP) [Internet]. [ cited 2017 Sep 1]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm
- FDA approval of an extended period for administering varizig for postexposure prophylaxis of varicella [Internet]. [ cited 2017 Sep 1]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6112a4.htm?s_cid=mm6112a4_w
- Lu P-L, Tsai J-C, Chiu Y-W, et al. Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant. 2008;23:1659–1665.
- Obadia T, Opatowski L, Temime L, et al. Interindividual contacts and carriage of Methicillin-resistant Staphylococcus aureus: A nested case-control study. Infect Control Hosp Epidemiol. 2015;36:922–929.
- Paranthaman K, Bentley A, Milne LM, et al. Nosocomial outbreak of staphyloccocal scalded skin syndrome in neonates in England, December 2012 to March 2013. Euro Surveill. 2014 Aug 21;19(33). pii: 20880.
- Olsen K, Sangvik M, Simonsen GS, et al. Prevalence and population structure of Staphylococcus aureus nasal carriage in healthcare workers in a general population. The Tromsø Staph and skin study. Epidemiol Infect. 2013;141:143–152.
- Galdys AL, Curry SR, Harrison LH. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Rev Anti Infect Ther. 2014;12:967–980.
- van Nood E, van Dijk K, Hegeman Z, et al. Asymptomatic carriage of Clostridium difficile among HCWs: do we disregard the doctor? Infect Control Hosp Epidemiol. 2009;30:924–925.
- Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med. 2015;372:846–854.
- Al-Gethamy M, Corman VM, Hussain R, et al. A Case of Long-term Excretion and Subclinical Infection With Middle East Respiratory Syndrome Coronavirus in a Healthcare Worker. Clin Infect Dis. 2015;60:973–974.
- Modjarrad K. MERS-CoV vaccine candidates in development: the current landscape. Vaccine. 2016;34:2982–2987.
- Sukhrie FHA, Teunis P, Vennema H, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54:931–937.
- Aliabadi N, Lopman BA, Parashar UD, et al. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Rev Vaccines. 2015;14:1241.
- Home | AMR Review [Internet]. [ cited 2017 Jan 24]. Available from: https://amr-review.org/
- Française LD. Tous ensemble, sauvons les antibiotiques - propositions du groupe de travail spécial pour la préservation des antibiotiques [Internet]. [ cited 2017 Jan 30]. Available from: http://www.ladocumentationfrancaise.fr/rapports-publics/154000669/index.shtml
- Skull SA, Andrews RM, Byrnes GB, et al. Missed opportunities to vaccinate a cohort of hospitalised elderly with pneumococcal and influenza vaccines. Vaccine. 2007;25:5146–5154.
- Bratzler DW, Houck PM, Jiang H, et al. Failure to vaccinate medicare inpatients: a missed opportunity. Arch Intern Med. 2002;162:2349–2356.
- Walton S, Elliman D, Bedford H. Missed opportunities to vaccinate children admitted to a paediatric tertiary hospital. Arch Dis Child. 2007;92:620–622.